Invesco Ltd. Has $204,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT)

Invesco Ltd. grew its holdings in MaxCyte, Inc. (NASDAQ:MXCT) by 8.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 49,096 shares of the company’s stock after purchasing an additional 3,848 shares during the quarter. Invesco Ltd.’s holdings in MaxCyte were worth $204,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. River Global Investors LLP grew its position in shares of MaxCyte by 57.7% during the 4th quarter. River Global Investors LLP now owns 3,253,192 shares of the company’s stock worth $13,494,000 after buying an additional 1,190,630 shares during the period. Royce & Associates LP grew its holdings in MaxCyte by 146.9% during the 4th quarter. Royce & Associates LP now owns 799,873 shares of the company’s stock worth $3,327,000 after acquiring an additional 475,949 shares during the period. Rice Hall James & Associates LLC bought a new stake in shares of MaxCyte during the 4th quarter valued at $1,098,000. Gagnon Securities LLC raised its position in shares of MaxCyte by 234.1% during the 4th quarter. Gagnon Securities LLC now owns 197,326 shares of the company’s stock valued at $821,000 after acquiring an additional 138,257 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of MaxCyte by 329.3% in the 3rd quarter. Barclays PLC now owns 165,765 shares of the company’s stock valued at $645,000 after purchasing an additional 127,156 shares during the period. Institutional investors own 68.81% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MXCT. Stifel Nicolaus decreased their price objective on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 12th. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the stock a “buy” rating in a research report on Wednesday, March 12th.

MaxCyte Stock Performance

Shares of NASDAQ MXCT opened at $2.82 on Monday. The stock has a 50 day moving average price of $2.92 and a 200 day moving average price of $3.66. The stock has a market capitalization of $299.81 million, a PE ratio of -8.29 and a beta of 1.39. MaxCyte, Inc. has a 52 week low of $2.21 and a 52 week high of $5.26.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.